Sartorius AG VZO O.N. (SRT)
XETRA Stock Exchange · Germany · prices in EUR · close of 22 Oct 2026
Key indicators
| Last close | EUR 217.00 |
|---|---|
| 52-week range | 158.20 – 222.00 |
| Return, 1 month / 3 months | +6.1% / +21.0% |
| Return, 1 year / 3 years | +12.6% / +9.8% |
| Trend | Uptrend |
| RSI (14) | 66 |
| Volatility (1 year) | 39.1% |
| Worst drawdown (1 year) | -20.3% |
| Average daily value traded | 0.62M EUR |
| Dividend yield | 0.3% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Sartorius is a German supplier of laboratory and process technology, based in Göttingen. It makes equipment used in pharmaceutical and biopharmaceutical production, such as bioreactors, filtration systems, fermentation hardware and laboratory balances, along with services that support these instruments. Its customers are mainly drug makers, biotechnology firms and research laboratories that use the equipment in development work and in manufacturing. The company also supplies products for quality control and laboratory analysis, serving customers in healthcare and life-science research around the world.
On this site Sartorius AG VZO O.N. appears as a stock on the XETRA Stock Exchange (Germany), code SRT, with prices in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Sartorius AG VZO O.N. (SRT) trades on the XETRA Stock Exchange in Germany. It last closed at EUR 217.00 on 22 October 2026.
Its price-based Market X-Ray is 68 out of 100 (a fair price profile), ranking 136 of 701 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 12.6% and over the last three months it rose 21.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on XETRA Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 85 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 16.4% | ||
| From 52-week high | 0.0% | ||
| Momentum | 76 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 21.0% | ||
| 6-month return | 16.9% | ||
| 12-month return, skipping the last month | 6.1% | ||
| Stability (higher is calmer) | 59 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 39.1% | ||
| Worst drawdown, 1 year (smaller is calmer) | -20.3% | ||
| Liquidity | 67 · Fair | Moderate trading activity. | |
| Average daily value traded | 0.62M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 27 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.3% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | +3.8% |
|---|---|
| 1 month | +6.1% |
| 3 months | +21.0% |
| 6 months | +16.9% |
| 1 year | +12.6% |
| 3 years | +9.8% |
| 5 years | −62.0% |
Signals
| 50-day / 200-day average | 198.21 / 186.39 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | Yes |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 7.21 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 27 Mar 2026 | EUR 0.7300 |
| 28 Mar 2025 | EUR 0.7300 |
| 2 Apr 2024 | EUR 0.7300 |
| 30 Mar 2023 | EUR 1.4300 |
| 28 Mar 2022 | EUR 1.2500 |
| 29 Mar 2021 | EUR 0.7000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on XETRA Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.